ViiV opens up brand-new HIV med Tivicay for cheap copies in poor countries

HIV drug specialist ViiV Healthcare has tossed a brand-new product into the Medicines Patent Pool. ViiV--a joint venture of GlaxoSmithKline ($GSK), Pfizer ($PFE) and Shionogi--inked a deal with MPP to speed access to cheap copies of Tivicay (dolutegravir) in developing countries. Among the pricier HIV treatments, Tivicay was FDA-approved last year, and analysts figure it could hit $5 billion in sales. Report

Suggested Articles

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Novartis is touting 52-week data for Cosentyx in spondyloarthritis—an indication where Eli Lilly's Taltz recently scored a trailblazing FDA approval.

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.